Search the Newsreel

Merck & Co., Inc. 2026: Revenue $16.61B, EPS ($0.54) — 10-Q Summary

Merck & Co., Inc. reported Q2 2026 results with revenue of $16.61 billion, a 5.1% increase year-over-year, but net income swung to a loss of ($1.34 billion) and diluted EPS was ($0.54). Revenue growth was driven by oncology, cardiometabolic/respiratory products, and animal health, with …

Merck (NYSE: MRK) EVP Guindo Chirfi sells 15,000 company shares

Merck & Co., Inc. EVP Guindo Chirfi sold 15,000 shares of common stock on August 6, 2026, at a price of $131.00 per share. This transaction, classified as an open-market or private sale, resulted in Chirfi directly owning 46,613 shares of Merck common stock …

How Merck & Company Inc. (MRK) Affects Rotational Strategy Timing

This article analyzes Merck & Company Inc. (MRK) for rotational strategy timing, indicating a neutral sentiment for near and mid-term, with a potential long-term positive bias. It highlights a significant short setup opportunity with a 25.3:1 risk-reward ratio and provides distinct AI-generated trading strategies …

Merck (MRK) Could Be 3% Undervalued On Raised Outlook And Key Drug Approvals

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Merck (MRK) is back in focus after a run of product and earnings headlines. …

Merck & Company, Inc. (MRK) Stock Forecasts

Morningstar has released an analyst report for Merck & Co., Inc. (MRK), maintaining a steady quarter but raising the forecast for its biggest pipeline opportunity. Merck specializes in pharmaceutical products, with its immuno-oncology platform, notably Keytruda, being a significant sales contributor. The report provides …

PensionDanmark Pensionsforsikringsaktieselskab Buys 54,260 Shares of Merck & Co., Inc. $MRK

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Merck & Co., Inc. by 13.3% during the second quarter, purchasing an additional 54,260 shares, bringing their total holdings to 462,927 shares valued at $59.49 million. The article also details recent analyst ratings, highlighting both positive developments like …

Sarasin & Partners LLP Sells 49,029 Shares of Merck & Co., Inc. $MRK

Sarasin & Partners LLP has reduced its stake in Merck & Co., Inc. by selling 49,029 shares, now holding 736,662 shares valued at approximately $94.7 million. Despite this sale, institutional investors collectively own 76.07% of the company. Wall Street analysts maintain a "Moderate Buy" …

Assenagon Asset Management S.A. Raises Stock Holdings in Merck & Co., Inc. $MRK

Assenagon Asset Management S.A. significantly increased its stake in Merck & Co., Inc. by 263.7% in the second quarter, now owning 2,702,992 shares valued at $347.33 million. The article also details other institutional investor activity, Merck's financial performance, recent dividend announcement, and various analyst …

Czech National Bank Acquires 27,039 Shares of Merck & Co., Inc. $MRK

The Czech National Bank increased its stake in Merck & Co., Inc. (NYSE:MRK) by 4.0% in the second quarter, acquiring an additional 27,039 shares to hold a total of 703,007 shares valued at $90,336,000. Several other institutional investors also adjusted their holdings in MRK. …

Merck lifts 2026 outlook as profits surge &Bio-Techne deal strengthens growth push

Merck has raised its full-year guidance for 2026 after reporting stronger-than-expected second-quarter results, driven by growth in life science, rare diseases, and semiconductor solutions. The company's proposed acquisition of Bio-Techne Corporation is expected to further bolster its leadership in high-growth life science markets. Merck …

Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive

Pfizer, Merck, and Amgen are expanding their cancer portfolios, leading to increased speculation about smaller oncology companies like Sellas Life Sciences (SLS) and ImmunityBio (IBRX) being potential acquisition targets. Pfizer's Seagen portfolio and Padcev, Merck's sac-TMT, and Amgen's T-cell engagers and Imdelltra are key …

This Biotech Dealmaker — Tied To Merck, Travere — Is In A Profit-Taking Zone

Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike. Continue Reading

Merck Animal Health awards $50,000 in vet scholarships

Merck Animal Health has awarded $50,000 in scholarships to five veterinary students specializing in poultry health, in partnership with the American Association of Avian Pathologists (AAAP) Foundation. This marks the 11th year of the program, which has now distributed over $280,000. The recipients were …

Merck KGaA (MKGAF) (Q2 2026) Earnings Call Highlights: Robust Growth and Raised Guidance Signal ...

This article first appeared on GuruFocus. Net Sales: Increased from EUR5,255 million in Q2 2025 to EUR5,434 million in Q2 2026, with organic sales growth of 4.1%. EBITDA pre: Increased from EUR1.46 billion to EUR1.6 billion, with organic growth of 9.3% and reported growth …

Why This Biotech Dealmaker — Tied To Merck, Travere — Charged Higher

Ligand stock bounded out of a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike. Continue Reading

Merck KGaA hebt nach starkem Q2 die Prognose für 2026 an

Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Let's …

Merck bid to expand label for RSV shot under FDA review (MRK)

Merck announced that the FDA has accepted its marketing application to expand the U.S. label for Enflonsia, its RSV antibody therapy. The treatment aims to protect infants from the respiratory syncytial virus. The prophylactic treatment had been previously approved by the FDA.

Merck KGaA gibt Ergebnisprognose für das Jahr 2026 ab

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

EMA also accepts application for the same population for ENFLONSIA based on results from the Phase 3 SMART trial If approved, children under two years of age at increased risk for severe RSV disease will be eligible to receive an additional dose of ENFLONSIA …

Merck KGaA Q2 adjusted profit rises 9%, hikes FY outlook

Investing.com-- Merck clocked a stronger second-quarter adjusted profit on Tuesday, aided by strong performances in its life science and electronics divisions, with the company also raising its annual profit outlook. Adjusted earnings before interest, tax, depreciation and amortization rose 9.4% year-on-year to 1.6 billion …

Merck KGaA steigert bereinigtes Ergebnis im 2. Quartal um 9 % und hebt Jahresprognose an

Levi & Korsinsky Notifies Shareholders of Merck & Co., Inc. (MRK) of a Class Action Lawsuit and an Upcoming Deadline

Levi & Korsinsky is notifying shareholders of Merck & Co., Inc. (MRK) about a class action lawsuit filed against the company. The lawsuit alleges securities fraud between February 3, 2022, and February 3, 2025, related to Merck's projected Gardasil revenue in China. Shareholders who …

Merck (MRK) Is Racing Beyond Keytruda As Its Biggest Patent Cliff Nears

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) is approaching a major patent cliff for cancer drug Keytruda from 2028. The company is increasing acquisitions and partnerships to broaden …

Health Canada Approves KEYTRUDA® for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment

KIRKLAND, QC, Aug. 4, 2026 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab for injection), Merck's anti-PD-1 therapy, in combination with enfortumab vedotin, an antibody-drug conjugate (ADC), is approved by Health Canada as …

MRK Q2 Earnings Call Puts Pipeline Progress in Focus

Merck & Co., Inc. MRK used its second-quarter 2026 call to stress faster pipeline progress and launch execution. Management raised the sales outlook even as acquisition charges produced a quarterly loss. The call also focused on LIPFENDRA access, KEYTRUDA's loss-of-exclusivity transition and whether newer …

JPMorgan Adjusts Price Target on Merck & Co. to $150 From $140, Maintains Overweight Rating

JPMorgan has increased its price target for Merck & Co. (NYSE:MRK) to $150 from $140, while reaffirming an Overweight rating on the stock. This adjustment indicates a positive outlook on the company's future performance.

Merck & Co., Inc. Q2 Earnings Call Highlights

Merck & Co., Inc. reported Q2 revenue of $16.6 billion, a 5% increase year-over-year, primarily driven by strong oncology, animal health, and new product sales. Despite a $0.13 per-share loss due to a $5.7 billion charge from the Terns Pharmaceuticals acquisition, the company raised …

Key facts: Merck & Co., Inc. Q2 Sales $16.6B; sac-TMT Advances

Merck & Co. (MRK) reported Q2 sales of $16.6 billion, a 5% year-over-year increase, with Keytruda sales reaching $8.4 billion and Winrevair at $588 million, up 75%. The company posted a GAAP net loss of $1.34 billion and an adjusted loss of $0.13 per …

MERCK & CO INC : JP MORGAN RAISES TARGET PRICE TO $150 FROM $140

JP Morgan has raised its target price for Merck & Co Inc (MRK.N) to $150 from the previous $140. This adjustment reflects an updated outlook from the financial institution regarding the pharmaceutical company's stock performance. The news was reported by Reuters.

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Merck & Co., Inc. (NYSE: MRK) announced its second-quarter 2026 financial results, reporting sales of $16.6 billion, a 5% increase year-over-year. The company posted a GAAP loss per share of $0.54 and a non-GAAP loss per share of $0.13, primarily due to a significant …

Merck & Co Inc (MRK) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ...

This article first appeared on GuruFocus. Total Revenue: $16.6 billion, an increase of 5% (4% excluding foreign exchange). KEYTRUDA Family Sales: Increased 4% to $8.4 billion, driven by uptake in earlier-stage cancers and robust demand from metastatic indications. KEYTRUDA QLEX Sales: $463 million, with …

Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says

Merck's (MRK) "HIV pipeline" is brewing in the background, as weekly treatment are interesting and s PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Merck & Co., Inc. actualiza sus previsiones de beneficios para 2026

Merck & Co., Inc. aktualisiert Ergebnisprognose für 2026

Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats

Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both ph PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …